Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Launches FoundationOne Liquid CDx Cancer Genomic Profile as the First Blood-based Comprehensive Genomic Profiling Test for Solid Tumors in Japan

08/02/2021 | 02:12am EDT

Chugai Launches FoundationOne Liquid CDx Cancer Genomic Profile as the First Blood-based Comprehensive Genomic Profiling Test for Solid Tumors in Japan

  • FoundationOne Liquid CDx Cancer Genomic Profile is now available for use as a comprehensive genomic profiling test covering 324 genes as well as a companion diagnostic to identify patients who may benefit from certain approved targeted therapies across multiple cancer indications

TOKYO, August 2, 2021 - Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced today that it has launched FoundationOne® Liquid CDx Cancer Genomic Profile as a liquid biopsy-based comprehensive genomic profiling (CGP) test for solid tumor, following the product's listing on the national health insurance (NHI) reimbursement price list on August 1, 2021. In addition, SRL Inc., the clinical laboratory testing company has started providing testing services for the product today. FoundationOne Liquid CDx Cancer Genomic Profile was approved by the Ministry of Health, Labour and Welfare (MHLW) on March 22, 2021 for use as a companion diagnostic (CDx) for certain approved targeted therapies in Japan, making it the first MHLW-approvedblood-based test with both CDx and solid tumor CGP indications.

"We are very pleased that we can start providing FoundationOne Liquid CDx Cancer Genomic Profile, a blood-based CGP testing option for patients today. The test provides meaningful information that can help inform treatment for patients with advanced or recurrent cancer, which is especially valuable if they are not eligible for tissue-based CGP testing," said Chugai's president and CEO Dr. Osamu Okuda. "We are committed to advance personalized healthcare through expanding access to CGP testing."

Developed by Foundation Medicine Inc.based in Cambridge, USA, FoundationOne Liquid CDx Cancer Genomic Profile is a blood-based diagnostic test that uses next-generation sequencing. It identifies genomic alterations in 324 cancer-related genes for cancer patients with solid tumors through detection of blood circulating tumor DNA (ctDNA). FoundationOne Liquid CDx Cancer Genomic Profile provides an integrated test report informing alterations matched to MHLW-approved targeted therapies.

As a leading company in the field of oncology, Chugai is committed to advance personalized healthcare in oncology and contributing to patients and healthcare professionals through improving access to CGP.

Approval information

Brand name

FoundationOne® Liquid CDx Cancer Genomic Profile

Japanese

Software for gene variants analysis (for cancer genome profiling)

medical device

Software for analysis of somatic cell gene variants (for eligibility

nomenclature

identification of antineoplastic agents)

(JMDN)

Intended uses or

The Product is used for comprehensive genomic profiling of blood

indications

samples in patients with solid tumors.

  • The Product is used for detecting gene mutations and other alterations to support the assessment of drug indications listed in the table below.

Alterations

Cancer type

Relevant drugs

Activated EGFR alterations

Non-small cell

afatinib maleate, erlotinib

lung cancer

hydrochloride, gefitinib,

(NSCLC)

osimertinib mesilate

EGFR exon 20 T790M

osimertinib mesilate

alterations

ALK fusion genes

alectinib hydrochloride,

crizotinib, ceritinib

ROS1 fusion genes

entrectinib

NTRK1/2/3 fusion gene

Solid tumors

entrectinib

BRCA1/2 alteration

Prostate cancer

olaparib

Conditions for

1. The necessary measures must be taken to ensure that the product is

approval

used by a physician with adequate knowledge and experience of

cancer genomic medicine at a medical institution with a cancer

genome profiling-based medical system pursuant to the "Guidelines for

the Development of Core Hospitals and Other Facilities for Cancer

Genomic Medicine," and in compliance with the scope and timing of

testing stipulated in the most recent guidelines, etc., of relevant

academic societies.

  1. Appropriate procedures and controls to protect personal information and up-to-date security and privacy protection measures to prevent unauthorized access must be implemented for blood samples sent to the laboratory and for information obtained from these specimens.
  2. Quality control of input data must be performed as described in the Remarks column of the attached Application Form. Any changes to the quality control of input data as described in the Remarks column of the Application Form (excluding minor changes specified by Order of the MHLW in Article 23-2-5, paragraph (15) of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices ["the Act"]) must be approved by the MHLW Minister pursuant to Article 23-2-5, paragraph (15) of the Act. Note that this approval applies mutatis mutandis to the provisions of Article 23-2-5 paragraph (17), Article 23-2-6, and Article 23-2-7 of the Act.

2/ 3

Date of NHI

August 1, 2021

reimbursement

price listing:

About FoundationOne Liquid CDx Cancer Genomic Profile

Developed by Foundation Medicine Inc.based in Cambridge, USA, FoundationOne Liquid CDx Cancer Genomic Profile is a next-generation sequencing based in vitro diagnostic device using blood samples for advanced cancer patients with solid tumors. It is intended to identify genomic alterations in 324 cancer-related genes through detection of blood circulating tumor DNA (ctDNA). The test is approved by the MHLW for use in cancer genome profiling to report substitutions, insertion and deletion alterations, and select gene rearrangements for short variants in 324 genes. It is also indicated for use as a companion diagnostic to identify patients who may benefit from treatment with specific targeted therapies (listed in Table above of Intended uses or indications). For the latest information about the product, including companion diagnostic indications, please refer to the prescribing information.

Trademarks used or mentioned in this release are protected by laws.

###

3/ 3

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 02 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2021 06:11:07 UTC.


ę Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
09/24PRESS RELEASE : Roche presents new data at World -2-
DJ
09/22PRESS RELEASE : Roche launches three respiratory test panels on cobas 6800/8800 Systems in..
DJ
09/20PRESS RELEASE : New Phase III data support the -2-
DJ
09/17PRESS RELEASE : Roche receives positive CHMP -2-
DJ
09/15PRESS RELEASE : Roche opens access to pathology imaging tools to improve patient care
DJ
09/14PRESS RELEASE : Temedica develops new digital companion Brisa for people with multiple scl..
DJ
09/13CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
09/09PRESS RELEASE : Roche signs definitive share purchase agreement with long-term partner TIB..
DJ
09/08Nikkei 225 Up 0.9%, Tops 30,000, Extends Rally on New Government Hopes
MT
09/08Japan's Nikkei ends at near 6-month high on bargain hunting for cheap stocks
RE
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 882 B 7 965 M 7 965 M
Net income 2021 265 B 2 392 M 2 392 M
Net cash 2021 485 B 4 382 M 4 382 M
P/E ratio 2021 26,7x
Yield 2021 1,41%
Capitalization 7 077 B 63 921 M 63 895 M
EV / Sales 2021 7,47x
EV / Sales 2022 7,45x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 4 304,00 JPY
Average target price 4 696,92 JPY
Spread / Average Target 9,13%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-21.79%63 921
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037